July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018

Reduction of sub-retinal fluid associated with central serous chorioretinopathy after the use of topical non-steroidal anti-inflammatory medications
Author Affiliations & Notes
  • Kyle MacLean
    Ophthalmology, UT Health San Antonio, San Antonio, Texas, United States
  • Sepehr Bahadorani
    Ophthalmology, UT Health San Antonio, San Antonio, Texas, United States
  • Nathan Gresores
    Medical Center Ophthalmology Associates, San Antonio, Texas, United States
  • Kendall Wannamaker
    Ophthalmology, UT Health San Antonio, San Antonio, Texas, United States
  • Michael Singer
    Medical Center Ophthalmology Associates, San Antonio, Texas, United States
  • Footnotes
    Commercial Relationships   Kyle MacLean, None; Sepehr Bahadorani, None; Nathan Gresores, None; Kendall Wannamaker, None; Michael Singer, Aerpio (C), Aerpio (R), Alcon (F), Alimera (C), Allegro (F), Allergan (C), Ampio (C), Clearside (C), Genentech (C), Genentech (R), Genentech (F), Guidepoint (C), Notal Vision (C), Optos (F), Regeneron (R), Santen (C), Santen (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3127. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kyle MacLean, Sepehr Bahadorani, Nathan Gresores, Kendall Wannamaker, Michael Singer;
      Reduction of sub-retinal fluid associated with central serous chorioretinopathy after the use of topical non-steroidal anti-inflammatory medications. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3127.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
Central serous chorioretinopathy (CSC) is among the most common retinopathies, yet there is no generally accepted treatment for the initial presentation of CSC. The purpose of this study was to evaluate the effect of topical NSAIDs on sub-retinal fluid as well as any difference in using one of three topical NSAIDs commercially available. We hypothesize that topical NSAIDs are likely to cause a greater reduction in sub-retinal fluid compared to observation alone.

Methods :
An IRB-approved retrospective review was conducted on patients that were diagnosed with a new case of CSC, were followed with optical coherence tomography (OCT) scans, and given either topical NSAIDs (bromfenac, nepafenac 0.1%, or nepafenac 0.3%) or observed without therapy. The primary outcomes include central macular thickness (CMT), height of sub-retinal fluid at its maximal point, and volume of sub-retinal fluid before and after therapy or observation. Volume and height analysis on the OCT scans were performed using imageJ software. Statistical significance was determined using one analysis of variance [ANOVA].

Results : A total of 27 patient (27 eyes) charts from two different clinical sites were reviewed, with 14 having been treated with topical NSAIDs and 13 observed only. OCTs of each patient were analyzed at presentation and then compared between the groups after 7 weeks of the initiation of treatment or observation. Reduction in the CMT in the treatment group was 200.6 micrometers (mm) vs 43.5 mm in the observation group (p<0.006). Reduction of sub-retinal fluid height was 61.1% in the treatment group vs 23.5% in the observation group (p<0.03). Change in the volume of sub-retinal fluid was 64.3% in the treatment group vs 11.1% in the observation group (p<0.02). There was no statistically significant change in the reduction of sub-retinal fluid within the treatment group between those treated with bromfenac, nepafenac 0.1%, or nepafenac 0.3% (p<0.10).

Conclusions :
Results of this study show that that use of topical NSAIDs in the treatment of acute CSC cause a greater decrease in sub-retinal fluid in a shorter period of time when compared to observation alone and may be an effective treatment for acute CSC. It also demonstrates that there is no significant difference between the three topical NSAIDs evaluated in this study.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×